We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-10.25%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.19B
AUM Growth
-$1.8B
Cap. Flow
-$1.09B
Cap. Flow %
-34.19%
Top 10 Hldgs %
52.73%
Holding
142
New
9
Increased
15
Reduced
47
Closed
31

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$32.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$32.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.9M
4
LLY icon
Eli Lilly
LLY
+$30M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.9M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$39.4M
4
NVRO
NEVRO CORP.
NVRO
+$34.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$32.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.5%
2 Financials 0.29%
3 Consumer Discretionary 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
126
DELISTED
NEVRO CORP.
NVRO
– –
-477,037
Closed -$34.5M
NARI
127
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-30,000
Closed -$2.72M
AXNX
128
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-341,211
Closed -$21.4M
HLTH
129
DELISTED
Cue Health Inc. Common Stock
HLTH
– –
-1,580,607
Closed -$10.2M
NVTA
130
DELISTED
Invitae Corporation
NVTA
– –
-554,585
Closed -$4.42M
SLGCW
131
DELISTED
SomaLogic, Inc. Warrant
SLGCW
– –
-110,000
Closed -$235K
UTRS
132
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
– –
-2,513
Closed -$226K
RETA
133
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-44,475
Closed -$1.46M
DALS
134
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
– –
-500,000
Closed -$4.86M
ONCR
135
DELISTED
Oncorus, Inc.
ONCR
– –
-752,241
Closed -$1.34M
SMIHU
136
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
– –
-1,000,000
Closed -$9.78M
RKLY.WS
137
DELISTED
Rockley Photonics Holdings Limited Warrants, each warrant exercisable for one ordinary share at an exercise price of $11.50
RKLY.WS
– –
-500,000
Closed -$425K
RACB
138
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
– –
-1,000,000
Closed -$9.76M
BLSA
139
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-1,000,000
Closed -$9.87M
HZNP
140
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-1,357,903
Closed -$143M
2 3 4 5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Perceptive Advisors held 142 positions worth $3.19B, down 36% from $4.99B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors withdrew a net $1.09B in Q2 2022, closing 31 positions and reducing 47 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Seagen Inc. Common Stock worth $39.6M.

  • Perceptive Advisors's largest Q2 2022 buy was Seagen Inc. Common Stock: 224,000 shares worth $39.6M.
  • Perceptive Advisors added most to LYRA THERAPEUTICS INC in Q2 2022, an estimated $32.3M increase.
  • Perceptive Advisors's biggest Q2 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $52.9M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, selling an estimated $143M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.19B portfolio in Q2 2022.
  • Perceptive Advisors opened 9 new positions and closed 31 in Q2 2022.
  • Perceptive Advisors's portfolio value fell 36% quarter-over-quarter to $3.19B.

Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.